| 产品描述： | Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research |
| 靶点： |
DNA/RNA Synthesis;Bacterial;Apoptosis;Antibiotic;Apoptosis; DNA/RNASynthesis; Antibacterial; Antibiotic |
| 体内研究： |
Fidaxomicin (0-5 mg/kg, Orally, once a day for 5 days) completely prevents the lethality of the animals and prevents the occurrence of relapses in a hamster model for pseudomembranous colitis |
| 参考文献： |
1. Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48. 2. Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. 3. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. 4. Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. |
| 溶解性： |
DMSO : ≥ 33 mg/mL (31.19 mM) |
| 保存条件： |
2-8℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
0.945 ml |
4.726 ml |
9.451 ml |
| 5 mM |
0.189 ml |
0.945 ml |
1.89 ml |
| 10 mM |
0.095 ml |
0.473 ml |
0.945 ml |
| 50 mM |
0.019 ml |
0.095 ml |
0.189 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京